Virax Biolabs Ownership
| VRAX Stock | USD 0.96 0.04 4.35% |
Virax Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.73. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virax Biolabs Group recorded a loss per share of 1.62. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of December 2023. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. Virax Biolabs is traded on NASDAQ Exchange in the United States. For more information please call James Foster at 44 20 7788 7414 or visit https://viraxbiolabs.com.Besides selling stocks to institutional investors, Virax Biolabs also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Virax Biolabs' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Virax Biolabs' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Virax Biolabs Quarterly Liabilities And Stockholders Equity |
|
About 7.0% of Virax Biolabs Group are currently held by insiders. Unlike Virax Biolabs' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Virax Biolabs' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Virax Biolabs' insider trades
Virax Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Virax Biolabs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Virax Biolabs Group backward and forwards among themselves. Virax Biolabs' institutional investor refers to the entity that pools money to purchase Virax Biolabs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Squarepoint Ops Llc | 2024-12-31 | 0.0 | Xtx Topco Ltd | 2025-03-31 | 0.0 | Northwestern Mutual Wealth Management Co | 2025-03-31 | 0.0 | Ubs Group Ag | 2025-03-31 | 22.4 K | Two Sigma Securities, Llc | 2025-03-31 | 13.6 K | Citadel Advisors Llc | 2025-03-31 | 13.5 K | Hrt Financial Llc | 2025-03-31 | 13.5 K | Royal Bank Of Canada | 2025-03-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | R Squared Ltd | 2025-03-31 | 0.0 |
Virax Biolabs Outstanding Bonds
Virax Biolabs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Virax Biolabs Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Virax bonds can be classified according to their maturity, which is the date when Virax Biolabs Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.